GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Medexus Pharmaceuticals Inc (OTCPK:MEDXF) » Definitions » Cyclically Adjusted PB Ratio

MEDXF (Medexus Pharmaceuticals) Cyclically Adjusted PB Ratio : 2.09 (As of May. 31, 2025)


View and export this data going back to 2017. Start your Free Trial

What is Medexus Pharmaceuticals Cyclically Adjusted PB Ratio?

As of today (2025-05-31), Medexus Pharmaceuticals's current share price is $2.11. Medexus Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2024 was $1.01. Medexus Pharmaceuticals's Cyclically Adjusted PB Ratio for today is 2.09.

The historical rank and industry rank for Medexus Pharmaceuticals's Cyclically Adjusted PB Ratio or its related term are showing as below:

MEDXF' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.79   Med: 1.96   Max: 11.37
Current: 1.91

During the past years, Medexus Pharmaceuticals's highest Cyclically Adjusted PB Ratio was 11.37. The lowest was 0.79. And the median was 1.96.

MEDXF's Cyclically Adjusted PB Ratio is ranked worse than
50.51% of 683 companies
in the Drug Manufacturers industry
Industry Median: 1.88 vs MEDXF: 1.91

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Medexus Pharmaceuticals's adjusted book value per share data for the three months ended in Dec. 2024 was $1.340. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $1.01 for the trailing ten years ended in Dec. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Medexus Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Medexus Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medexus Pharmaceuticals Cyclically Adjusted PB Ratio Chart

Medexus Pharmaceuticals Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 10.16 1.10 1.15

Medexus Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.77 1.15 1.29 1.86 2.40

Competitive Comparison of Medexus Pharmaceuticals's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Medexus Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medexus Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Medexus Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Medexus Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


;
;

Medexus Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Medexus Pharmaceuticals's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=2.11/1.01
=2.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medexus Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2024 is calculated as:

For example, Medexus Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Dec. 2024 was:

Adj_Book=Book Value per Share/CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=1.34/127.3637*127.3637
=1.340

Current CPI (Dec. 2024) = 127.3637.

Medexus Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201503 0.737 99.789 0.941
201506 0.513 100.500 0.650
201509 0.357 100.421 0.453
201512 0.175 99.947 0.223
201603 0.447 101.054 0.563
201606 0.693 102.002 0.865
201609 0.583 101.765 0.730
201612 0.428 101.449 0.537
201703 0.201 102.634 0.249
201706 0.694 103.029 0.858
201709 0.689 103.345 0.849
201712 0.552 103.345 0.680
201803 0.404 105.004 0.490
201806 0.313 105.557 0.378
201809 -0.148 105.636 -0.178
201812 2.849 105.399 3.443
201903 1.899 106.979 2.261
201906 1.773 107.690 2.097
201909 1.828 107.611 2.164
201912 1.634 107.769 1.931
202003 1.680 107.927 1.983
202006 1.402 108.401 1.647
202009 1.286 108.164 1.514
202012 0.297 108.559 0.348
202103 0.940 110.298 1.085
202106 0.598 111.720 0.682
202109 1.219 112.905 1.375
202112 1.160 113.774 1.299
202203 0.892 117.646 0.966
202206 0.880 120.806 0.928
202209 0.847 120.648 0.894
202212 0.766 120.964 0.807
202303 1.112 122.702 1.154
202306 1.121 124.203 1.150
202309 0.913 125.230 0.929
202312 1.209 125.072 1.231
202403 1.240 126.258 1.251
202406 1.332 127.522 1.330
202409 1.328 127.285 1.329
202412 1.340 127.364 1.340

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Medexus Pharmaceuticals  (OTCPK:MEDXF) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Medexus Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Medexus Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Medexus Pharmaceuticals Business Description

Traded in Other Exchanges
Address
10 King Street East, Suite 600, Toronto, ON, CAN, M5C 1C3
Medexus Pharmaceuticals Inc is a specialty pharmaceutical company with a powerful North American commercial platform and a growing portfolio of inventive and rare disease treatment solutions. The company's focus is on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology.